Full Press Release Details
Tranche B warrants to purchase up to 1,097,394 shares of common stock at a cash exercise price of $9.1125 per share for an aggregate of up to $10.0 million and will expire at the earlier of (i) 30 days following the announcement of the RP2D for the Company's WEE1 inhibitor program, APR-1051, and the daily VWAP of the Company's common stock equaling or exceeding $18.225 per share for 30 consecutive trading days following the announcement and (ii) five years from the date of issuance 23 2026 Aprea Therapeutics, Inc.
Patent 10,301,324 Family 3: ATR Inhibitor Pharmaceutical Composition and Methods - International application filed on Apr. 14th, 2023 - Pharmaceutical formulation and composition of our lead molecule in the clinic - Nationalizations pending for US, AU, BR, CA, CN, EA, EP, IL, IN, JP, KR, MX, NZ, PH, SG, ZA Family 4: WEE1 Inhibitor Pharmaceutical Compositions and Methods - International Application filed on Jun. 3rd, 2022 - Composition of our lead WEE1 inhibitor compounds - Nationalizations in US, AU, BR, CA, CN, EP, IL, IN, JP, KR, MX, ZA Family 5: Methods of Treating Cancer - U.S.
Patent 9,663,535 - 1.2: Issued on May 29, 2018 as U.S. Patent 9,981,989 - 1.3: Issued on Feb. 5, 2019 as U.S. Patent 10,196,405 Family 2: ATR Inhibitors and Methods of Use - Carboxylic acid-containing macrocyclic ATR inhibitors, and prodrugs; methods of using these inhibitors to treat various cancers; filed on Apr. 12th, 2017 - Issued on May 28th, 2019 as U.S.
Potential Combinations - Radiation therapy - Antibody drug conjugates - Immuno-oncology Twice-daily dosing Once-daily dosing Cleared New Enrollment Paused** Dose level 6 400 mg Dose level 8 550 mg 5/2 Dose level 9 650 mg 5/2 Dose level 7 550 mg* Dose level 10 750 mg 5/2 Phase 1 Dose Escalation Phase 2 Combination Studies*** * Dose not tolerated ** Further monotherapy enrollment paused, with consideration of further ATRN-119 development in combination approaches that could expand its therapeutic potential *** Company currently in discussions with leading academic centers to consider combination studies with ATRN-119 8 subjects with stable disease and tumor shrinkage up to 21% Dose level 1 50 mg Dose level 2 100 mg Dose level 3 200 mg Dose level 4 350 mg Dose level 5 550 mg Dose level 6 800 mg Dose level 7 1100 mg Dose level 8* 1300 mg RP2D 18 2026 Aprea Therapeutics, Inc.
Patient continues on treatment with manageable toxicity profile. Human Papillomavirus (HPV) Head and Neck Squamous Cell Carcinoma (HNSCC) Pre-clinical studies with APR-1051 Collaboration with MD Anderson APR-1051 shows single agent activity in HPV+ head and neck tumor cells APR-1051 shows single agent activity in head and neck tumor cells Start of treatment ** Control APR-1051 Data cut-off: Oct 20, 2025 15 2026 Aprea Therapeutics, Inc.
Zentalis deck - Azenosertib Clinical Development Update June 18, 2024 Multiple Phase 2 Studies Show Substantial Single-agent Activity with a WEE1 Inhibitor (Adavosertib1 ) Competitive WEE1 Inhibitors are associated with significant Grade 3 hematological, GI or CV toxicities 3,4,5 Aprea's WEE1 inhibitor is characterized by early single agent activity with potentially less off-target engagement and improved safety Phase 2 Study Indication Evaluable Patients (N) ORR NCT03668340 2 Recurrent uterine serous carcinoma 34 29.4% 1 CR 9 PR NCT03253679 3 Refractory solid tumors harboring CCNE1 amplification 30 Ovarian - 14, Breast - 3, Uterine - 3, Other - 10 All Pt: 27% (8 PR) Ovarian Pt: 36% (5 PR) 10 2026 Aprea Therapeutics, Inc.
Multicenter Phase II Trial of Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol (2022) 41:1725-1734 4. Gelderblom H, et al., "Debio 0123-101, A Phase 1 Trial of Debio 0123 in Combination with Carboplatin in Advanced Solid Tumors: Safety, Pharmacokinetic, and Preliminary Antitumor Activity Data" (Poster session presented at the annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, June 3 7, 2023) 5.
Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this presentation. We undertake no obligation to update such forward-looking statements for any reason, except as required by law. 3 2026 Aprea Therapeutics, Inc.
Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and our ability to predict clinical outcomes based on such preclinical and early clinical result, and our ability to continue as a going concern, and the other risks, uncertainties, and other factors described under Risk Factors, Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in the documents we file with the U.S.
All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
We may, in some cases use terms such as future, predicts, believes, potential, continue, anticipates, estimates, expects, plans, intends, targeting, confidence, may, could, might, likely, will, should or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties.